Due to today's unhealthy and stressful lifestyle and the proliferation of environmentally harmful & man-made toxic
chemicals in all forms, cancer is now considered one of the most prevalent, destructive
ailments known to man. Although cancer has been around since the earliest of our
ancestors, it is only now where we're experiencing its widespread effects. I'm
pretty sure each one of us has had a relative, friend or colleague who was
diagnosed with, or worse, killed by cancer. In an article published in Men's Health, cancer is now the leading cause of man's death next only to heart disease.
In a medical forum called "JOIN OUR BOWEL MOVEMENT" organized by Merck Serono, Philhealth and the Philippine Society of Medical Oncology attended by
this humble blogger, the seriousness and extent of cancer, specifically
colorectal cancer (CRC) or commonly known as colon cancer, was discussed
extensively.
Diagram of colorectal cancer |
Attending this forum was for me an eye-opener in terms of the
public's lack of information on its causes, cures and prevention. This dreaded
disease I found out can be cured if detected early with a simple screen test called KRAS or Kirsten Rat Sarcoma Viral
Oncogene Homology offered by both public and private hospitals. I was also
surprised by its availability and easy access. Well KRAS in my humble
understanding of the matter as provided by the event's press kit, is a post
test of CRC tumors that determines the best possible treatment for the disease. I am publishing below an actual photo/diagram of a colorectal cancer tumor to give you a scare and encourage you to get a screen test for CRC immediately (LOL).
Kidding aside, I asked Dr. Ramy Roxas, one of the resource speakers and president of the ASEAN Society of Colorectal Surgeons, on how to prevent this type of cancer and his answer was simple but very sensible, "Get yourself screened as soon as possible even if you don't feel any symptoms." Of course, this is aside from doing all the right stuff such as eating healthy, exercising daily and just adopting a healthy & fit lifestyle.
To understand more about this dreaded cancer and the best possible treatments and early interventions such as the KRAS & KRAS Testing, visit their website www.merck.ph, www.merckserono.com, or call their Philippine office numbers at (02) 815-4067 & (02) 818-3632.
I am also publishing the full press release of the event below to give you a better understanding of KRAS and colorectal cancer.
Again, I enjoin everyone especially my dear readers to always be aware of everything especially matters regarding one's health. Who knows? You might be facing a life and death situation. I never knew the dangers and prevalence of colorectal cancer if it weren't for this informative forum.
Be aware, spread the word and let's all join the "Bowel Movement"!
************************************************************************
Press Release
KRAS
biomarker guides Doctors on the most appropriate cancer therapy
Eight
years ago, Reynaldo G., a 52 year old businessmen thought he had everything
going great for him. His business was thriving well, he received awards for his
accomplishments, and he was at the peak of his career.
He
noted streaks of blood in his stools which he thought was just due to his
hemorrhoids. He underwent an executive check-up and after his colonoscopy, it
seemed like the world cave in on him when he was told by his attending
physician that he had a tumor in his colon or large intestines.
Biopsy
results confirmed that it was cancerous. He underwent surgery which cut a good
part of his intestines to get rid of the
cancerous mass completely. He also underwent a complete course of anti-cancer
chemotherapy. As of his latest check-up, there’s no indication of any tumor
recurrence, and he’s considered cured of his colon cancer.
Not
all patients with colorectal cancer (CRC) are as lucky as Reynaldo. Some are
diagnosed too late when the cancer has already spread to other parts of the
body; or for some, the cancer cells may not be that responsive to the chosen
chemotherapy.
A
host of medical experts an advocates
held a press conference on March 22 to raise awareness on CRC and a the first biomarker
in Metastatic Colorectal Cancer, which helps determine the best anti-cancer
therapy suitable for the patient who have a metastatic disease.
The
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homology) determines the specific
subtypes of CRC which will indicate the most suitable and effective targeted
treatment for the patient. The majority of patients with CRC are in the KRAS
Wild type (65 percent) while Mutant KRAS is found in 35 percent of cases.
Having the tumors screened for KRAS mutations after diagnosis of mCRC is
recommended before any treatment is done. This guides the doctor in determining
the most suitable anti-cancer therapy for the patient, sparing him or her from
unnecessary costs and side-effects.
The
Philippine Society of Medical Oncology, PhilHealth, and Merck Serono have
banded together in organizing “Join our Bowel Movement,” a press conference
with talks by the country’s top colorectal cancer experts and advocates.
Lectures
by Dr. Felycette Gay Lapus, Philippine Society of Medical Oncology (PSMO)
president; Dr. Ellie May B. Villegas, PSMO vice president; Dr. Ramy Roxas,
ASEAN society of Colorectal Surgeons president and TMC Colorectal Clinic
director; Merla Rose D. Reyes, RPh., PhilHealth Senior Social Insurance
Specialist; and Prof. Diena Oroceo, CRC survivor were held on topics ranging
from CRC treatment and diagnosis up to a CRC Survivor’s chronicle.
Dr.
Villegas talked about CRC screening and diagnosis in her “Check your Colon”
talk, and CRC treatment in her “Put your Rear on Gear” talk. Dr. Roxas
discussed surgery in CRC in “Cutting Edge” while Reyes talked about the
“Government Joining the Bowel Movement.” Prof. Oroceo shared CRC from a
survivor’s point-of-view.
CRC
begins when normal cells in the lining of the colon or rectum change and grow
uncontrollably, forming a polyp which grows to become a malignant tumor.
According
to Dr. Villegas, “Recent studies show that cetuximab and panitumamab do not
work as well for tumors that have specific mutations to a gene called KRAS.”
The
American Society of Clinical Oncology released a provisional clinical opinion
recommending that all patients with metastatic colorectal cancer who may
receive anti-EFGR therapy have their tumors tested for KRAS gene mutations.
KRAS
plays an important role in the epidermal growth factor receptor (EGFR)
signaling pathway. KRAS is a gene that codes one of the proteins of EGFR.
KRAS
protein regulates other proteins in the EGFR pathway, which is related to tumor
survival, angionesis, proliferation, and metastasis.
KRAS
genes come in two types – KRAS wild-type and mutant KRAS. KRAS protein in the
latter type has the KRAS protein perpetually “turned-on” and does not need
activation by an upstream EGFR-mediated signaling. KRAS wild-type on the other
hand means that the protein will only be temporarily activated in response to
stimuli like EGFR signaling.
XXX
By Paolo Angelo Florenda